Literature DB >> 7498458

Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain.

P C Schmid1, R J Krebsbach, S R Perry, T M Dettmer, J L Maasson, H H Schmid.   

Abstract

Long-chain N-acylethanolamines (NAEs) were assayed in pig, sheep and cow brain by gas chromatography/mass spectrometry of their tert.-butyldimethylsilyl derivatives in the presence of deuterium-labeled internal standards. Immediately after death, total NAEs ranged from about 2.7 micrograms/g wet weight (sheep, cow) to 6.5 micrograms/g wet weight (pig) and consisted almost exclusively (99%) of saturated and monounsaturated species. Anandamide (20:4n-6 NAE) comprised about 1% of total NAE in pig and cow brain, but was absent in freshly extracted sheep brain. When pig brain was analysed after 0.5, 1, 3, 4 and 23 h at ambient temperature, NAE levels were found to increase substantially over the entire time period with 20:4n-6 NAE formation exhibiting a time lag compared to that of saturated and monounsaturated NAEs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498458     DOI: 10.1016/0014-5793(95)01194-j

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  45 in total

1.  Levels of N-acylethanolamines in human tumors: in search of reliable data.

Authors:  Mauro Maccarrone; Filomena Fezza; Alessandro Finazzi-Agrò
Journal:  Lipids       Date:  2004-02       Impact factor: 1.880

2.  One pot direct synthesis of amides or oxazolines from carboxylic acids using Deoxo-Fluor reagent.

Authors:  Cyrous O Kangani; David E Kelley
Journal:  Tetrahedron Lett       Date:  2005-12-19       Impact factor: 2.415

Review 3.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

4.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

Review 5.  Targeting the endocannabinoid system in Alzheimer's disease.

Authors:  Jeremy Koppel; Peter Davies
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

6.  Lauroylethanolamide and linoleoylethanolamide improve functional outcome in a rodent model for stroke.

Authors:  Puja Garg; R Scott Duncan; Simon Kaja; Alexander Zabaneh; Kent D Chapman; Peter Koulen
Journal:  Neurosci Lett       Date:  2011-02-04       Impact factor: 3.046

Review 7.  Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases.

Authors:  Mario van der Stelt; Henrik H Hansen; Wouter B Veldhuis; Peter R Bär; Klaas Nicolay; Gerrit A Veldink; Johannes F G Vliegenthart; Harald S Hansen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.

Authors:  Giulio G Muccioli; Nephi Stella
Journal:  Anal Biochem       Date:  2007-09-29       Impact factor: 3.365

9.  Brain levels of N-acylethanolamine phospholipids in mice during pentylenetetrazol-induced seizure.

Authors:  Birthe Moesgaard; Henrik H Hansen; Suzanne L Hansen; Steen Honore Hansen; Gitte Petersen; Harald S Hansen
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

10.  Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain.

Authors:  M Palkovits; J Harvey-White; J Liu; Z S Kovacs; M Bobest; G Lovas; A G Bagó; G Kunos
Journal:  Neuroscience       Date:  2008-02-05       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.